JP6284547B2 - 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体 - Google Patents

置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体 Download PDF

Info

Publication number
JP6284547B2
JP6284547B2 JP2015549746A JP2015549746A JP6284547B2 JP 6284547 B2 JP6284547 B2 JP 6284547B2 JP 2015549746 A JP2015549746 A JP 2015549746A JP 2015549746 A JP2015549746 A JP 2015549746A JP 6284547 B2 JP6284547 B2 JP 6284547B2
Authority
JP
Japan
Prior art keywords
substituent
optionally substituted
alkyl
optionally
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015549746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505595A (ja
JP2016505595A5 (enExample
Inventor
ベイゲルマン，レオニード
ワン，グァンイー
バーナード スミス，デイビッド
バーナード スミス，デイビッド
Original Assignee
アリオス バイオファーマ インク．
アリオス バイオファーマ インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリオス バイオファーマ インク．, アリオス バイオファーマ インク． filed Critical アリオス バイオファーマ インク．
Publication of JP2016505595A publication Critical patent/JP2016505595A/ja
Publication of JP2016505595A5 publication Critical patent/JP2016505595A5/ja
Application granted granted Critical
Publication of JP6284547B2 publication Critical patent/JP6284547B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2015549746A 2012-12-21 2013-12-19 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体 Active JP6284547B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261745466P 2012-12-21 2012-12-21
US61/745,466 2012-12-21
US201361890125P 2013-10-11 2013-10-11
US61/890,125 2013-10-11
PCT/US2013/076740 WO2014100505A1 (en) 2012-12-21 2013-12-19 Substituted nucleosides, nucleotides and analogs thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017243925A Division JP6637023B2 (ja) 2012-12-21 2017-12-20 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体

Publications (3)

Publication Number Publication Date
JP2016505595A JP2016505595A (ja) 2016-02-25
JP2016505595A5 JP2016505595A5 (enExample) 2017-01-19
JP6284547B2 true JP6284547B2 (ja) 2018-02-28

Family

ID=50975302

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015549746A Active JP6284547B2 (ja) 2012-12-21 2013-12-19 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
JP2017243925A Active JP6637023B2 (ja) 2012-12-21 2017-12-20 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
JP2019229193A Active JP7196054B2 (ja) 2012-12-21 2019-12-19 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
JP2022149411A Pending JP2022180507A (ja) 2012-12-21 2022-09-20 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017243925A Active JP6637023B2 (ja) 2012-12-21 2017-12-20 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
JP2019229193A Active JP7196054B2 (ja) 2012-12-21 2019-12-19 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
JP2022149411A Pending JP2022180507A (ja) 2012-12-21 2022-09-20 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体

Country Status (31)

Country Link
US (12) US9243022B2 (enExample)
EP (3) EP3421482A1 (enExample)
JP (4) JP6284547B2 (enExample)
KR (4) KR102327888B1 (enExample)
CN (2) CN110684067A (enExample)
AP (1) AP2015008533A0 (enExample)
AU (3) AU2013361200A1 (enExample)
BR (1) BR112015014457A2 (enExample)
CA (1) CA2894542C (enExample)
CL (2) CL2015001699A1 (enExample)
CY (1) CY1124742T1 (enExample)
DK (1) DK2935303T3 (enExample)
EA (1) EA201590943A1 (enExample)
EC (1) ECSP15031144A (enExample)
ES (1) ES2865402T3 (enExample)
GE (1) GEP201706757B (enExample)
HR (1) HRP20210510T1 (enExample)
HU (1) HUE053946T2 (enExample)
IL (3) IL296551B2 (enExample)
LT (1) LT2935303T (enExample)
MX (1) MX2015007925A (enExample)
PE (1) PE20151433A1 (enExample)
PH (1) PH12015501423A1 (enExample)
PL (1) PL2935303T3 (enExample)
PT (1) PT2935303T (enExample)
RS (1) RS61767B1 (enExample)
SG (2) SG10201802325TA (enExample)
SI (1) SI2935303T1 (enExample)
SM (1) SMT202100259T1 (enExample)
TW (2) TWI641615B (enExample)
WO (1) WO2014100505A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018080178A (ja) * 2012-12-21 2018-05-24 アリオス バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52954B (sr) 2009-09-21 2014-02-28 Gilead Sciences Inc. Postupci i intermedijeri za proizvodnju 1'-cijanokarbanukleozidnih analoga
AP3269A (en) 2010-07-22 2015-05-31 Gilead Sciences Inc Methods and compounds for treating paramyxoviridaevirus infections
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
EP2655392B1 (en) 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
CN104114568B (zh) 2011-12-22 2017-09-01 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
EP2828277A1 (en) 2012-03-21 2015-01-28 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
WO2013174962A1 (en) 2012-05-25 2013-11-28 Janssen R&D Ireland Uracyl spirooxetane nucleosides
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
EP2935305A4 (en) 2012-12-21 2016-08-03 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUE THEREOF
EP2981542B1 (en) * 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US9504705B2 (en) 2013-04-05 2016-11-29 Alios Biopharma, Inc. Hepatitis C viral infection treatment using a combination of compounds
US20180200280A1 (en) * 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
WO2014186637A1 (en) * 2013-05-16 2014-11-20 Riboscience Llc 4'-fluor0-2'-methyl substituted nucleoside derivatives
AU2014302715B2 (en) 2013-06-26 2018-12-06 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA2913206C (en) 2013-06-26 2022-08-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10320532B2 (en) * 2013-10-04 2019-06-11 Lg Electronics Inc. Method whereby terminal transmits ACK/NACK in wireless communication system, and device therefor
WO2015054465A1 (en) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CR20160400A (es) 2014-02-06 2016-11-07 Riboscience Llc Derivados de nucleosido sustituidos con 4´-difluorometilo como inhibidores de la replicación de arn de la influenza
UA118380C2 (uk) 2014-06-17 2019-01-10 Пфайзер Інк. Заміщені сполуки дигідроізохінолінону
LT3160476T (lt) 2014-06-24 2021-04-12 Janssen Biopharma, Inc. Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme
AU2015280245A1 (en) * 2014-06-24 2017-01-05 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
EA201692537A1 (ru) 2014-06-24 2017-05-31 Элиос Биофарма, Инк. Замещенные нуклеозиды, нуклеотиды и их аналоги
HK1243714A1 (zh) 2014-10-28 2018-07-20 Alios Biopharma, Inc. 制备取代的核苷类似物的方法
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
CN104478976A (zh) * 2014-11-12 2015-04-01 苏州明锐医药科技有限公司 索非布韦的制备方法
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
LT3236972T (lt) 2014-12-26 2021-11-10 Emory University Antivirusiniai n4-hidroksicitidino dariniai
WO2016134054A1 (en) * 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
KR102363946B1 (ko) 2015-03-06 2022-02-17 아테아 파마슈티컬즈, 인크. HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
EA036776B1 (ru) 2015-03-11 2020-12-21 Янссен Байофарма, Инк. Соединения азапиридона и способы их применения
CN106146433B (zh) * 2015-03-26 2019-04-26 常州制药厂有限公司 一种索非布韦的中间体的制备方法
CA2997170A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral tetrahydrofurane derivatives
ES2918585T3 (es) 2015-09-16 2022-07-19 Gilead Sciences Inc Métodos para el tratamiento de infecciones por el virus Arenaviridae
US9988416B2 (en) 2016-03-24 2018-06-05 Novartis Ag Alkynyl nucleoside analogs as inhibitors of human rhinovirus
CN109689063A (zh) * 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
CN107337702B (zh) * 2016-04-29 2021-11-05 江苏豪森药业集团有限公司 结晶型hcv抑制剂及其制备方法和应用
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN106083773B (zh) * 2016-05-31 2019-06-14 杭州惠诺医药科技有限公司 3,5-二苯甲酰基-2-去氧-2-氟-2-甲基-D-核糖-γ-内酯的制备方法
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018017994A1 (en) * 2016-07-22 2018-01-25 Janssen Pharmaceuticals, Inc. Combination drug treatment for hepatitis c infection
CN109890831A (zh) 2016-08-12 2019-06-14 詹森生物制药有限公司 被取代的核苷、核苷酸以及它们的类似物
EP4088725A1 (en) 2016-09-07 2022-11-16 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family
CN110248951B (zh) 2017-02-01 2022-10-28 阿堤亚制药公司 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
CN115403626A (zh) 2017-05-01 2022-11-29 吉利德科学公司 新结晶形式
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
TWI860279B (zh) * 2017-09-21 2024-11-01 美商里伯賽恩斯有限責任公司 作為hcv rna複製抑制劑之經4'-氟-2'-甲基取代之核苷衍生物
CA3077213A1 (en) 2017-10-04 2019-04-11 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
EA202092117A1 (ru) * 2018-03-07 2021-06-28 Эмори Юниверсити Терапевтические композиции 4'-галогенсодержащих нуклеотидов и нуклеозидов и их применение
WO2019200005A1 (en) 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
WO2019237297A1 (en) * 2018-06-14 2019-12-19 Janssen Pharmaceuticals, Inc. Processes for preparing compounds/intermediates useful in the treatment of viral infections
KR20210154229A (ko) * 2019-04-22 2021-12-20 리간드 파마슈티칼스 인코포레이티드 사이클릭 포스페이트 화합물
KR20220024419A (ko) 2019-06-06 2022-03-03 어비디티 바이오사이언시스 인크. 핵산-폴리펩티드 조성물 및 이의 용도
KR20220035143A (ko) 2019-07-17 2022-03-21 누코리온 파마슈티컬스, 인코포레이티드. 사이클릭 디옥시리보뉴클레오티드 화합물
WO2021140471A1 (en) * 2020-01-10 2021-07-15 Janssen Biopharma, Inc. Method for synthesis of 2'-alkyl- or 2'-alkenyl- or 2'-alkynyl-4'-fluoro-adenosine derivatives and intermediates thereof
TWI789695B (zh) 2020-01-27 2023-01-11 美商基利科學股份有限公司 治療sars cov-2感染之方法
WO2021168004A1 (en) 2020-02-18 2021-08-26 Gilead Sciences, Inc. Antiviral compounds
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
TWI890963B (zh) 2020-03-12 2025-07-21 美商基利科學股份有限公司 1'-氰基核苷之製備方法
JP7482250B2 (ja) 2020-04-06 2024-05-13 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノ置換カルバヌクレオシド類似体の吸入製剤
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
KR102911165B1 (ko) 2020-06-24 2026-01-13 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오시드 유사체 및 이의 용도
CR20230100A (es) 2020-08-24 2023-04-28 Gilead Sciences Inc Compuestos fosfolípidos y usos de los mismos
HRP20240733T1 (hr) 2020-08-27 2024-08-30 Gilead Sciences, Inc. Spojevi i postupci za liječenje virusnih infekcija
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
AU2022256476B2 (en) 2021-04-16 2025-06-05 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CN113234102A (zh) * 2021-05-18 2021-08-10 宁波大学 一种三配位磷衍生物及中间体及制备方法
CA3174073A1 (en) 2021-06-17 2022-12-17 Atea Pharmaceuticals, Inc. Advantageous anti-hcv combination therapy
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CR20240363A (es) 2022-03-02 2024-10-25 Gilead Sciences Inc Compuestos y métodos para el tratamiento de infecciones virales.
CN116947947A (zh) 2022-04-20 2023-10-27 中国科学院上海药物研究所 抗病毒核苷类似物及其药物组合物和用途
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US112966A (en) * 1871-03-21 Improvement in hay and cotton-presses
US3817978A (en) 1971-06-16 1974-06-18 Syntex Inc 4-fluoro nucleosides and sugar intermediates, and methods of preparing
US3852267A (en) 1972-08-04 1974-12-03 Icn Pharmaceuticals Phosphoramidates of 3{40 ,5{40 -cyclic purine nucleotides
DE3239986A1 (de) 1982-10-28 1984-05-03 Robert Bosch Gmbh, 7000 Stuttgart Handwerkzeugmaschine mit einem kreisscheibenfoermigen werkzeug
US4713383A (en) 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US5712088A (en) 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5679342A (en) 1987-11-18 1997-10-21 Chiron Corporation Hepatitis C virus infected cell systems
US5714596A (en) 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
IN167775B (enExample) 1988-06-24 1990-12-22 Hoechst India
US6027729A (en) 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
DE3932052A1 (de) 1989-09-26 1991-04-04 Basf Ag Oxazol- bzw. thiazolcarbonsaeureamide
MY106399A (en) 1990-07-24 1995-05-30 Pfizer Cephalosporins and homologeus, preparation and pharmaceutical composition
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
JP2889408B2 (ja) 1991-09-17 1999-05-10 富士写真フイルム株式会社 アゾメチン化合物及びこれを含有する熱転写色素供与材料
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
AU729657B2 (en) 1992-05-11 2001-02-08 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
DE4232852A1 (de) 1992-09-30 1994-03-31 Bayer Ag Imidazolinyl-pyridazine
ZA943999B (en) 1993-06-09 1995-02-03 Lonza Ag Quaternary ammonium and waterproofing/preservative compositions
WO1995008540A1 (en) 1993-09-22 1995-03-30 The Wellcome Foundation Limited Bis(amidinobenzimidazolyl)alkanes as antiviral agents
DE4341161A1 (de) 1993-12-02 1995-06-08 Michael Prof Dr Zeppezauer Membrangängiger Wirkstoff zur Störung der DNA-Biosynthese
JPH07242544A (ja) 1994-03-01 1995-09-19 Takeda Chem Ind Ltd 抗腫瘍剤
CN1190198C (zh) 1996-01-23 2005-02-23 Icn药品公司 激活的T淋巴细胞中Ribavirin 和Ribavirin类似物对TH1/TH2细胞因子表达的调控
CA2266889A1 (en) 1996-10-16 1998-04-23 Guangyi Wang Purine l-nucleosides, analogs and uses thereof
SI20076A (sl) 1996-10-16 2000-04-30 Icn Pharmaceuticals, Inc. Monociklični L-nukleozidi, analogi in uporaba od teh
EP2253639A1 (en) 1997-09-12 2010-11-24 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
EP2390257A1 (en) 1998-02-25 2011-11-30 Emory University 2'-fluoronucleosides
US20030203862A1 (en) 1998-03-26 2003-10-30 Miraglia Loren J. Antisense modulation of MDM2 expression
AU4322799A (en) 1998-05-28 1999-12-13 Incara Pharmaceuticals Corp. Carbohydrate-based scaffold compounds, combinatorial libraries and methods for their construction
DE19855963A1 (de) 1998-12-04 2000-06-08 Herbert Schott Amphiphile Glycerylnucleotide, Verfahren zu ihrer Herstellung und ihre Verwendung
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
CA2372085C (en) 1999-05-04 2009-10-27 Exiqon A/S L-ribo-lna analogues
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
US6815542B2 (en) 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
GB0019124D0 (en) 2000-08-03 2000-09-27 Pfizer Novel process
CN101862345B (zh) 2000-10-18 2014-06-04 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
EA007491B1 (ru) 2001-01-22 2006-10-27 Мерк Энд Ко., Инк. Производные нуклеозидов в качестве ингибиторов рнк-зависимой рнк вирусной полимеразы
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US6962991B2 (en) 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
US7138376B2 (en) 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
EP1438054A4 (en) 2001-09-28 2006-07-26 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION
WO2003039523A2 (en) 2001-11-05 2003-05-15 Exiqon A/S OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
AT411065B (de) 2001-12-27 2003-09-25 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von heterocyclischen (r)- und (s)-cyanhydrinen
US7323453B2 (en) 2002-02-13 2008-01-29 Merck & Co., Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
US20120041184A1 (en) 2002-02-20 2012-02-16 Leonid Beigelman RNA INTERFERENCE MEDIATED INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2003213628A1 (en) 2002-02-28 2003-09-16 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
AU2003237249A1 (en) 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
AU2003269892A1 (en) 2002-06-27 2004-01-19 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
TW200500374A (en) 2002-06-28 2005-01-01 Idenlx Cayman Ltd 2' and 3' -nucleoside produrgs for treating flavivridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
AU2003269902A1 (en) 2002-07-16 2004-02-02 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004014312A2 (en) 2002-08-08 2004-02-19 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
US7393954B2 (en) 2002-12-12 2008-07-01 Reliable Biopharmaceutical Corporation Process for the production of pentostatin aglycone and pentostatin
AU2003225705A1 (en) 2003-03-07 2004-09-30 Ribapharm Inc. Cytidine analogs and methods of use
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
CA2522522A1 (en) 2003-04-16 2004-10-28 F. Hoffmann-La Roche Ag Quinazoline compounds
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
WO2005020884A2 (en) * 2003-05-14 2005-03-10 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
PT1633766T (pt) 2003-05-30 2019-06-04 Gilead Pharmasset Llc Análogos de nucleósido fluorado modificado
US7507859B2 (en) 2003-06-16 2009-03-24 Fifth Base Llc Functional synthetic molecules and macromolecules for gene delivery
EP1658302B1 (en) 2003-07-25 2010-08-25 IDENIX Pharmaceuticals, Inc. Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
BRPI0414019A (pt) 2003-08-27 2006-10-24 Biota Inc nucleosìdios ou nucleotìdio tricìclicos como agentes terapêuticos
AU2004280256A1 (en) 2003-10-08 2005-04-21 Organix, Inc. Pyrovalerone analogs and therapeutic uses thereof
EP1912643A2 (en) 2004-06-23 2008-04-23 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
WO2006012078A2 (en) 2004-06-24 2006-02-02 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2006063717A2 (en) 2004-12-16 2006-06-22 Febit Biotech Gmbh Polymerase-independent analysis of the sequence of polynucleotides
US8802840B2 (en) 2005-03-08 2014-08-12 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
US20100279974A1 (en) 2005-03-09 2010-11-04 Claire Pierra Nucleosides With Non-Natural Bases as Anti-Viral Agents
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
CA2610854A1 (en) 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
WO2006116512A1 (en) 2005-04-26 2006-11-02 The Board Of Trustees Of The University Of Illinois, Urbana, Il Nucleoside compounds and methods of use thereof
EP1928475B1 (en) 2005-08-15 2018-05-23 Riboscience LLC Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides
JP2009532448A (ja) 2006-04-03 2009-09-10 アストラゼネカ アクチボラグ 置換アデニンおよびそれらの使用
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
PT2084175E (pt) 2006-10-10 2011-04-01 Medivir Ab Inibidor nucleosídico de vhc
WO2008089439A2 (en) 2007-01-18 2008-07-24 Fred Hutchinson Cancer Research Center Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
EP2121719A2 (en) 2007-01-31 2009-11-25 Alios Biopharma, Inc. 2-5a derivatives and their use as anti-cancer, anti-viral and anti-parasitic agents
JP2008214305A (ja) 2007-03-07 2008-09-18 Kotobuki Seiyaku Kk 置換アミン誘導体及びこれを有効成分とする医薬組成物
WO2008117047A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolo[3, 4-d]pyrimidine derivatives as antibacterial compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20080255038A1 (en) 2007-04-11 2008-10-16 Samuel Earl Hopkins Pharmaceutical compositions
EP1980568A1 (de) 2007-04-13 2008-10-15 Eberhard Karls Universität Tübingen Ethinylierte Heterodinucleosidphosphatanaloga, Verfahren zu deren Herstellung und deren Verwendung
SI2014771T1 (sl) 2007-06-25 2015-04-30 Anadys Pharmaceuticals, Inc. Kontinuiran postopek encimske hidrolize
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
EP2019100A1 (en) 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
US20090076062A1 (en) 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
WO2009058800A2 (en) 2007-10-29 2009-05-07 President And Fellows Of Harvard College Synthesis of nucleosides
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US8293720B2 (en) 2007-12-20 2012-10-23 Dogwood Pharmaceuticals, Inc. Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
WO2009086192A1 (en) 2007-12-21 2009-07-09 Alios Biopharma, Inc. Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents
US20090181921A1 (en) 2007-12-21 2009-07-16 Alios Biopharma Inc. 2-5a analogs and their methods of use
CL2009000400A1 (es) 2008-02-22 2010-09-10 Irm Llc Compuestos heterociclicos derivados de 3-fenil-1,6- naftiridin-2-ona; moduladores de la actividad cinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos alergicos, trastornos autoinmunes, neoplasias, rechazo en trasplante de organos, entre otras.
WO2009129120A2 (en) 2008-04-15 2009-10-22 Rfs Pharma, Llc Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
GB0815968D0 (en) 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
US20110171192A1 (en) 2008-09-05 2011-07-14 Hiroshi Tomiyama Substituted amine derivative and medicinal composition comprising same as the active ingredient
TW201023858A (en) * 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
CN102753563A (zh) 2008-12-23 2012-10-24 吉利德制药有限责任公司 核苷类似物
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
BRPI1005401A2 (pt) 2009-02-06 2019-04-02 Rfs Pharma, Llc pro-farmácos de purina nucleosídeo monofosfato para o tratamento de câncer e infecções virais
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
WO2010108135A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Protected nucleotide analogs
WO2010108140A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
EP2264169A1 (en) 2009-06-15 2010-12-22 Qiagen GmbH Modified siNA
US20100331397A1 (en) 2009-06-24 2010-12-30 Alios Biopharma, Inc. 2-5a analogs and their methods of use
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
EP2483288B1 (en) * 2009-09-29 2016-11-16 Janssen Products, L.P. Phosphoramidate derivatives of nucleosides
US20150018301A1 (en) 2009-11-06 2015-01-15 The Johns Hopkins University LRRK-2-Mediated Neuronal Toxicity
EP2550260A1 (en) 2010-03-24 2013-01-30 Medical University Of South Carolina Compositions and methods for the treatment of degenerative diseases
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
FR2960235B1 (fr) 2010-05-18 2013-11-01 Inst Francais Du Petrole Procede d'oligomerisation des olefines utilisant une composition comprenant un complexe organometallique contenant un ligand alcoxy fonctionnalise par un hetero-atome.
FR2960234B1 (fr) 2010-05-18 2013-11-01 Inst Francais Du Petrole Procede de dimerisation de l'ethylene en butene-1 utilisant une composition comprenant un complexe a base de titane et un ligand alcoxy fonctionnalise par un hetero-atome.
US9090642B2 (en) 2010-07-19 2015-07-28 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
AP3269A (en) 2010-07-22 2015-05-31 Gilead Sciences Inc Methods and compounds for treating paramyxoviridaevirus infections
WO2012016713A1 (en) 2010-08-05 2012-02-09 Ruprecht-Karls-Universität Heidelberg Tumour targeting with polypeptides
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
US20120070411A1 (en) 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
AR083221A1 (es) 2010-09-29 2013-02-06 Univ Nac Quilmes Proceso para producir dialquilfosfotriesteres de nucleosidos mediante transesterificacion enzimatica y desproteccion de los mismos para producir nucleosidos monofosfato
US20120082795A1 (en) 2010-10-01 2012-04-05 Ppg Industries Ohio, Inc. Method for using a primer comprising a self-emulsified polyester microgel
WO2012074547A2 (en) 2010-11-29 2012-06-07 New York University STEROID COMPOUNDS AS RORγt MODULATORS AND USES THEREOF
EP2655392B1 (en) 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
CN103403014B (zh) 2011-01-03 2016-07-06 河南美泰宝生物制药有限公司 O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途
US9289445B2 (en) 2011-01-20 2016-03-22 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
CN103717222A (zh) 2011-02-24 2014-04-09 浙江大学 桥二硫二氧代哌嗪及其在治疗癌症方面的用途
WO2012142523A2 (en) 2011-04-13 2012-10-18 Gilead Sciences, Inc. 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
JP2014515023A (ja) 2011-04-13 2014-06-26 メルク・シャープ・アンド・ドーム・コーポレーション ２’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法
WO2012167133A2 (en) 2011-06-01 2012-12-06 The Regents Of The University Of California Inhibitors of anandamide transport and their therapeutic uses
FR2977586B1 (fr) 2011-07-08 2013-07-12 Rhodia Operations Procede de fabrication de composes comprenant des fonctions nitriles
DE102011108874A1 (de) 2011-07-28 2013-01-31 Hydac System Gmbh Steuervorrichtung
US9334300B2 (en) 2011-08-01 2016-05-10 Mbc Pharma, Inc. Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
WO2013044030A1 (en) * 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. 2'-chloroacetylenyl substituted nucleoside derivatives
CN103102345B (zh) 2011-11-14 2015-06-03 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
FR2982858B1 (fr) 2011-11-18 2013-11-29 Rhodia Operations Procede de fabrication de composes comprenant des fonctions nitriles
FR2984322B1 (fr) 2011-12-16 2013-12-20 Rhodia Operations Procede de fabrication de composes comprenant des fonctions nitriles
PT2794629T (pt) * 2011-12-20 2017-07-20 Riboscience Llc Derivados de nucleósidos substituídos em 2¿-4¿-difluor-2¿-metilo, como inibidores da replicação do arn de vhc (vírus da hepatite c)
CN104114568B (zh) 2011-12-22 2017-09-01 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
WO2013138210A1 (en) 2012-03-14 2013-09-19 Ning Xi Substituted cyclic compounds and methods of use
EP2828277A1 (en) 2012-03-21 2015-01-28 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
HK1203513A1 (en) 2012-03-21 2015-10-30 艾丽奥斯生物制药有限公司 Methods of preparing substituted nucleotide analogs
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
MX361460B (es) 2012-03-21 2018-12-06 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos.
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
US9809616B2 (en) 2012-10-29 2017-11-07 Emory University Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer
AU2013266393B2 (en) 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
EP2676987A1 (en) 2012-06-21 2013-12-25 Universidad De Burgos Cross-linked aramid
US20150183818A1 (en) 2012-07-03 2015-07-02 Bristol-Myers Squibb Company Process for preparing diastereomerically enriched phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
AU2013305759C1 (en) 2012-08-23 2018-01-18 Janssen Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
WO2014047117A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Process for preparing phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
AU2013324681B2 (en) 2012-09-26 2017-08-10 Merck Patent Gmbh Quinazolinone derivatives as PARP inhibitors
BR112015006019B1 (pt) 2012-09-26 2021-01-05 F. Hoffmann-La Roche Ag composto e uso de um composto
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
WO2014100425A1 (en) 2012-12-20 2014-06-26 Aldexa Therapeutics, Inc. Peri-carbinols
CN110684067A (zh) 2012-12-21 2020-01-14 艾丽奥斯生物制药有限公司 取代的核苷和核苷酸
US11639333B2 (en) 2012-12-21 2023-05-02 Celgene Quanticel Research, Inc Histone demethylase inhibitors
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
EP2935305A4 (en) 2012-12-21 2016-08-03 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUE THEREOF
KR102173874B1 (ko) 2012-12-21 2020-11-05 에피자임, 인코포레이티드 테트라하이드로- 및 디하이드로-이소퀴놀린 prmt5 억제제 및 이의 용도
FR3000065A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
MX2015008077A (es) 2012-12-21 2015-10-30 Sanofi Sa Derivados de exendina-4 como agonistas dobles de glp1/gip o trigonal de glp1-gip/glucagon.
DK2935312T3 (en) 2012-12-21 2018-10-22 Hoffmann La Roche Peptides as oxytocin agonists
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
JP6385954B2 (ja) 2012-12-21 2018-09-05 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節のための化合物および方法、ならびにその適応
LU92126B1 (fr) 2012-12-31 2014-07-01 Cesa Alliance Sa Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
EP2964631B1 (de) * 2013-03-04 2017-08-30 Bayer Animal Health GmbH Halogen-substituierte n-[3-(1h-pyrazol-4-yl)phenylmethyl]-sulfonamid-derivate und verwandte verbindungen als pestizide zur verwendung im pflanzenschutz, in der veterinärmedizin und im materialschutz
US20140309413A1 (en) 2013-03-11 2014-10-16 Vertex Pharmaceuticals Incorporated Methods of stereoselective synthesis of substituted nucleoside analogs
US9504705B2 (en) 2013-04-05 2016-11-29 Alios Biopharma, Inc. Hepatitis C viral infection treatment using a combination of compounds
WO2014186637A1 (en) 2013-05-16 2014-11-20 Riboscience Llc 4'-fluor0-2'-methyl substituted nucleoside derivatives
AU2014302715B2 (en) 2013-06-26 2018-12-06 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA2913206C (en) 2013-06-26 2022-08-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015026792A1 (en) 2013-08-21 2015-02-26 Alios Biopharma, Inc. Antiviral compounds
JP6448647B2 (ja) 2013-09-12 2019-01-09 アリオス バイオファーマ インク． アザ−ピリドン化合物およびその用途
CA2922943A1 (en) 2013-09-12 2015-03-19 Alios Biopharma, Inc. Pyridazinone compounds and uses thereof
WO2015054465A1 (en) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
LT3160476T (lt) * 2014-06-24 2021-04-12 Janssen Biopharma, Inc. Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme
EA201692537A1 (ru) 2014-06-24 2017-05-31 Элиос Биофарма, Инк. Замещенные нуклеозиды, нуклеотиды и их аналоги
MX2017000983A (es) 2014-07-22 2017-09-01 Alios Biopharma Inc Metodos para tratar el paramixovirus.
CA2957017A1 (en) 2014-08-05 2016-02-11 Alios Biopharma, Inc. Combination therapy for treating a paramyxovirus
HK1243714A1 (zh) 2014-10-28 2018-07-20 Alios Biopharma, Inc. 制备取代的核苷类似物的方法
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
EA036776B1 (ru) 2015-03-11 2020-12-21 Янссен Байофарма, Инк. Соединения азапиридона и способы их применения
JP6860585B2 (ja) 2016-03-09 2021-04-14 ヤンセン バイオファーマ インク． 非環状抗ウイルス 優先出願の参照による組み込み
WO2017156407A1 (en) 2016-03-10 2017-09-14 Alios Biopharma, Inc. Method of preparing aza-pyridone compounds
WO2017223231A1 (en) 2016-06-21 2017-12-28 Alios Biopharma, Inc. (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza
WO2018081449A1 (en) 2016-10-27 2018-05-03 Alios Biopharma, Inc. Methods for treating respiratory syncytial virus infection
WO2018222774A1 (en) 2017-05-30 2018-12-06 Alios Biopharma, Inc. Methods for treating pneumoviruses
US20220033406A1 (en) 2018-12-12 2022-02-03 Janssen Biopharma, Inc. Cyclopentyl nucleoside analogs as anti-virals
MX2021006992A (es) 2018-12-12 2021-11-17 Janssen Biopharma Inc Análogos de nucleósidos de ciclobutilo como antivirales.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018080178A (ja) * 2012-12-21 2018-05-24 アリオス バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
JP2020063284A (ja) * 2012-12-21 2020-04-23 ヤンセン バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
US11485753B2 (en) 2012-12-21 2022-11-01 Janssen Pharmaceutica Nv Substituted nucleosides, nucleotides and analogs thereof
JP7196054B2 (ja) 2012-12-21 2022-12-26 ヤンセン バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
US12173025B2 (en) 2012-12-21 2024-12-24 Janssen Pharmaceuticals, Inc. Substituted nucleosides, nucleotides and analogs thereof

Also Published As

Publication number Publication date
CL2015001699A1 (es) 2015-10-30
JP2016505595A (ja) 2016-02-25
PE20151433A1 (es) 2015-10-16
EP3421482A1 (en) 2019-01-02
US20160024136A1 (en) 2016-01-28
US10144755B2 (en) 2018-12-04
CN105073766A (zh) 2015-11-18
US20140179910A1 (en) 2014-06-26
CL2017001769A1 (es) 2018-02-16
KR102168621B1 (ko) 2020-10-22
EP2935303A1 (en) 2015-10-28
SG10201802325TA (en) 2018-04-27
CN110684067A (zh) 2020-01-14
ES2865402T3 (es) 2021-10-15
IL274901B (en) 2022-10-01
ECSP15031144A (es) 2015-11-30
HUE053946T2 (hu) 2021-08-30
PL2935303T3 (pl) 2021-10-04
DK2935303T3 (da) 2021-05-03
WO2014100505A1 (en) 2014-06-26
KR102788773B1 (ko) 2025-03-28
JP7196054B2 (ja) 2022-12-26
US20190031703A1 (en) 2019-01-31
JP6637023B2 (ja) 2020-01-29
US10112966B2 (en) 2018-10-30
US20200079813A1 (en) 2020-03-12
CA2894542C (en) 2023-10-31
EP3912984A1 (en) 2021-11-24
IL296551B2 (en) 2024-04-01
HRP20210510T1 (hr) 2021-05-14
KR102532198B1 (ko) 2023-05-11
PT2935303T (pt) 2021-04-30
US20160039858A1 (en) 2016-02-11
BR112015014457A2 (pt) 2017-11-21
AU2018203337B2 (en) 2019-12-05
US20160016987A1 (en) 2016-01-21
US12173025B2 (en) 2024-12-24
US10793591B2 (en) 2020-10-06
SMT202100259T1 (it) 2021-07-12
CY1124742T1 (el) 2022-07-22
TW201429983A (zh) 2014-08-01
KR102327888B1 (ko) 2021-11-17
MX2015007925A (es) 2015-10-05
JP2018080178A (ja) 2018-05-24
IL296551A (en) 2022-11-01
JP2022180507A (ja) 2022-12-06
KR20150100806A (ko) 2015-09-02
US9243022B2 (en) 2016-01-26
SI2935303T1 (sl) 2021-08-31
US10683320B2 (en) 2020-06-16
US20210139523A1 (en) 2021-05-13
US20230167151A1 (en) 2023-06-01
SG11201504554UA (en) 2015-07-30
US9249174B2 (en) 2016-02-02
IL274901A (en) 2020-07-30
AU2013361200A1 (en) 2015-07-23
AU2020200499B2 (en) 2021-05-06
RS61767B1 (sr) 2021-05-31
EP2935303B1 (en) 2021-02-17
US20170037075A1 (en) 2017-02-09
IL239324A0 (en) 2015-07-30
GEP201706757B (en) 2017-10-25
US20140179627A1 (en) 2014-06-26
KR20200120776A (ko) 2020-10-21
AU2020200499A1 (en) 2020-02-13
IL239324B (en) 2020-11-30
HK1216536A1 (en) 2016-11-18
TWI641615B (zh) 2018-11-21
CA2894542A1 (en) 2014-06-26
TW201900182A (zh) 2019-01-01
EA201590943A1 (ru) 2016-01-29
LT2935303T (lt) 2021-03-25
IL274901B2 (en) 2023-02-01
IL296551B1 (en) 2023-12-01
US20190085011A1 (en) 2019-03-21
PH12015501423A1 (en) 2015-09-14
KR20230069261A (ko) 2023-05-18
US11485753B2 (en) 2022-11-01
AU2018203337A1 (en) 2018-05-31
KR20210141773A (ko) 2021-11-23
US10487104B2 (en) 2019-11-26
US20170037077A1 (en) 2017-02-09
EP2935303A4 (en) 2016-08-10
JP2020063284A (ja) 2020-04-23
AP2015008533A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
JP7196054B2 (ja) 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
HK40064928A (en) 4’-fluoro-nucleosides, 4’-fluoro-nucleotides and analogs thereof for the treatment of hcv
HK1216536B (en) 4'-fluoro-nucleosides, 4'-fluoro-nucleotides and analogs thereof for the treatment of hcv
OA17338A (en) Substituted nucleosides, nucleotides and analogs thereof.

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20160819

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160926

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180130

R150 Certificate of patent or registration of utility model

Ref document number: 6284547

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250